Quantifying Preferences for CAR‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma

ABSTRACT Background CAR‐T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early‐line MM raises questions on the acceptability of upfront risks in exchange for extended relapse‐free pe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jessie Sutphin, Thomas W. LeBlanc, Ellen Janssen, Laura Hester, Matthew J. Wallace, F. Reed Johnson, Shelby D. Reed
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-07-01
coleção:	Cancer Medicine
Assuntos:	benefit–risk CAR‐T discrete‐choice experiment multiple myeloma patient preferences
Acesso em linha:	https://doi.org/10.1002/cam4.71072
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!